The relationship between prostate‐specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate‐specific antigen levels

Abstract

Patients with prostate cancer with a PSA level <3.5 ng/ml at diagnosis had a more advanced stage of cancer compared with those with a PSA level between 3.5 and 10 ng/ml. Therefore, risk classification using PSA levels at diagnosis may need to take into consideration this specific PSA range in order to better predict survival.